Pfizer takes its option in AnTolRx deal; Secura Bio scores access to $145M for cancer drug launches
→ Two-and-a-half years after Pfizer stepped up to seed the biotech startup AnTolRx, the pharma giant has stepped in to take their option on an immune tolerance therapy for Type 1 diabetes. Based on the lab work of Francisco Quintana, a professor of neurology at Brigham and Women’s Hospital in Boston — who’s specialized in antigen-specific tolerance — AnTolRx has been working on a pipeline of immune tolerance therapies for autoimmune and inflammatory ailments. The biotech is picking up an unspecified upfront payment in the deal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.